{
    "clinical_study": {
        "@rank": "57032", 
        "arm_group": [
            {
                "arm_group_label": "Desloratadine 10 mg", 
                "arm_group_type": "Experimental", 
                "description": "Desloratadine 10 mg administered orally once daily for up to 2 weeks."
            }, 
            {
                "arm_group_label": "Desloratadine 5 mg", 
                "arm_group_type": "Experimental", 
                "description": "Desloratadine 5 mg administered orally once daily for up to 2 weeks."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Matching placebo to desloratadine administered orally once daily."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a study to evaluate the efficacy and safety of desloratadine in Japanese\n      participants with perennial allergic rhinitis. The primary hypothesis is that desloratadine\n      is superior to placebo after 2 weeks of treatment with regard to change from baseline in\n      total nasal symptom score among Japanese participants with perennial allergic rhinitis."
        }, 
        "brief_title": "A Study of the Efficacy and Safety of Desloratadine (MK-4117) in Japanese Participants With Perennial Allergic Rhinitis (MK-4117-200)", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "condition": "Perennial Allergic Rhinitis", 
        "condition_browse": {
            "mesh_term": [
                "Rhinitis", 
                "Rhinitis, Allergic, Perennial"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosed with  perennial allergic rhinitis;\n\n          -  Outpatient.\n\n        Exclusion Criteria:\n\n          -  Participants with lower respiratory tract infection and participants who have a\n             nasopharyngolaryngeal infection (acute upper respiratory tract infection, acute\n             pharyngolaryngitis, or acute tonsillitis, etc.)\n\n          -  History of hypersensitivity to antihistamines or study drug;"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "12 Years"
        }, 
        "enrollment": {
            "#text": "608", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01918033", 
            "org_study_id": "4117-200", 
            "secondary_id": [
                "MK-4117-200", 
                "132244"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Desloratadine 10 mg", 
                "description": "Desloratadine 10 mg once daily for up to 2 weeks.", 
                "intervention_name": "Desloratadine 10 mg", 
                "intervention_type": "Drug", 
                "other_name": "MK-4117"
            }, 
            {
                "arm_group_label": "Desloratadine 5 mg", 
                "description": "Desloratadine 5 mg once daily for up to 2 weeks.", 
                "intervention_name": "Desloratadine 5 mg", 
                "intervention_type": "Drug", 
                "other_name": "MK-4117"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Matching placebo to desloratadine once daily for up to 2 weeks.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Histamine Antagonists", 
                "Desloratadine", 
                "Loratadine", 
                "Histamine H1 Antagonists", 
                "Cholinergic Antagonists", 
                "Neurotransmitter Agents", 
                "Histamine H1 Antagonists, Non-Sedating"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Rhinitis", 
            "Allergic Rhinitis", 
            "Nose Diseases", 
            "Respiratory Tract Diseases", 
            "Immune System Diseases", 
            "Cholinergic Antagonists", 
            "Cholinergic Agents", 
            "Neurotransmitter Agents", 
            "Histamine H1 Antagonists, Non-Sedating", 
            "Histamine H1 Antagonists", 
            "Histamine Antagonists", 
            "Histamine Agents"
        ], 
        "lastchanged_date": "February 6, 2014", 
        "number_of_arms": "3", 
        "official_title": "A Phase III, Multi-Center, Randomized, Parallel-Group, Placebo-Controlled and Double- Blind Trial to Study the Efficacy and Safety of MK-4117 in Japanese Subjects With Perennial Allergic Rhinitis", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Change From Baseline in Total Nasal Symptom Score Assessed by the Investigator at Week 2", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 2"
            }, 
            {
                "measure": "Percentage of Participants Experiencing an Adverse Event (AE)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Week 4"
            }, 
            {
                "measure": "Percentage of Participants Discontinuing Study Treatment Due to an AE", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Week 2"
            }
        ], 
        "removed_countries": {
            "country": "Japan"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01918033"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change From Baseline in Total Nasal Symptom Score Assessed by the Investigator", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Day 3, Week 1"
            }, 
            {
                "measure": "Change From Baseline in Nasal Symptom Sub-Score Assessed by the Investigator", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Day 3, Week 1, Week 2"
            }, 
            {
                "measure": "Change From Baseline in Nasal Finding Score Assessed by the Investigator", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Day 3, Week 1, Week 2"
            }, 
            {
                "measure": "Change From Baseline in Eye Symptom Score Assessed by the Investigator", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Day 3, Week 1, Week 2"
            }, 
            {
                "measure": "Percentage of Participants With Moderate-to-Remarkable Improvement in 5 Ratings of Global Improvement Rate Assessed by the Investigator", 
                "safety_issue": "No", 
                "time_frame": "Day 3, Week 1, Week 2"
            }, 
            {
                "measure": "Change From Baseline in Score on Interference With Daily Activities Assessed by the Investigator", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Day 3, Week 1, Week 2"
            }, 
            {
                "measure": "Change From Baseline in Nasal Symptom Score Reported in Participant Diaries", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Day 3, Week 1, Week 2"
            }, 
            {
                "measure": "Change From Baseline in Eye Symptom Score Reported in Participant Diaries", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Day 3, Week 1, Week 2"
            }
        ], 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}